Affordable Access

Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience.

Authors
Type
Published Article
Journal
Diabetes Care
0149-5992
Publisher
American Diabetes Association
Publication Date
Volume
15
Issue
5
Pages
666–692
Identifiers
PMID: 1516487
Source
Medline
License
Unknown

Abstract

To obtain an independent review of the risks and benefits of HPI, in February 1988, Lilly convened a consultant group that examined all relevant information on HPI available. These experts shared our concerns about the safety of HPI in light of the failure to demonstrate unique efficacy. Accordingly, clinical trials with HPI were suspended in February 1988. Experience with HPI demonstrates the challenge associated with the development of new drugs in general and insulin agonists in particular.

Statistics

Seen <100 times